Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series

Overview of attention for article published in Frontiers in oncology, June 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (54th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 9,163 followers.

Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series #lymphoma #lymsm https://t.co/tRQKVJ59aM

05 Jul 2022

Reply Repost Favourite

05 Jul 2022

Reply Repost Favourite

PubMed_ Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series https://t.co/0CuMYBcYHK

05 Jul 2022

Reply Repost Favourite

New research: Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series: Background Relapsed/refractory (r/r) primary central… https://t.co/keic

16 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.